Related Experiment Video

Updated: Mar 5, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Channelopathies, genetic testing and risk stratification

Arthur A M Wilde1, Ahmad Amin2

  • 1Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands; Princess Al-Jawhara Albrahim Centre of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia.

International Journal of Cardiology
|March 28, 2017
PubMed

Insights

Cardiac channelopathies, like Long QT Syndrome, have specific ECG traits and sudden cardiac death risks. Genetic discoveries in cardiogenetics now enable early detection and personalized treatments for these heart rhythm disorders.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Cardiac channelopathies are a group of inherited heart diseases characterized by specific electrocardiographic (ECG) findings and a risk of sudden cardiac death (SCD).
  • Key examples include Long QT Syndrome (LQTS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Brugada Syndrome (BrS), Short QT Syndromes (SQTS), and Early Repolarization Syndrome (ERS).
  • Significant advancements in understanding the genetic basis of these conditions have established the field of Cardiogenetics.

Purpose of the Study:

  • To review the impact of genetic discoveries on understanding and managing cardiac channelopathies.
  • To highlight how genetic information aids in identifying at-risk individuals and guiding treatment strategies.
  • To discuss the role of genetic insights in predicting the risk of life-threatening arrhythmias.

Main Methods:

  • Review of recent literature on the genetic underpinnings of cardiac channelopathies.
  • Analysis of the clinical implications of genetic discoveries in cardiogenetics.
  • Synthesis of information regarding gene-specific diagnosis and risk stratification.

Main Results:

  • The genetic basis for major cardiac channelopathies has been largely elucidated over the past two decades.
  • Genetic identification allows for presymptomatic carrier detection and timely intervention.
  • Genetic insights have revealed distinct pathophysiological substrates, leading to gene-specific and novel treatment approaches.
  • Genetic information is crucial for predicting the risk of lethal ventricular arrhythmias in affected individuals.

Conclusions:

  • The field of Cardiogenetics has revolutionized the diagnosis and management of cardiac channelopathies.
  • Genetic testing is essential for accurate diagnosis, risk stratification, and personalized treatment of inherited arrhythmia syndromes.
  • Continued research in cardiogenetics promises further advancements in preventing sudden cardiac death.

Keywords:
BrSCPVTChannelopathyERSLQTSRisk stratificationSQTS

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
64
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
65
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
71
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
586
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.2K